Section Arrow
INZY.NASDAQ
- Inozyme Pharma
Quotes are at least 15-min delayed:2024/12/23 22:13 EST
Last
 3.01
+0.02 (+0.67%)
Day High 
3.035 
Prev. Close
2.99 
1-M High
3.46 
Volume 
361.89K 
Bid
3.01
Ask
3.08
Day Low
2.825 
Open
3.01 
1-M Low
2.385 
Market Cap 
192.08M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.92 
20-SMA 2.79 
50-SMA 3.7 
52-W High 7.795 
52-W Low 2.385 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.55/-1.74
Enterprise Value
237.76M
Balance Sheet
Book Value Per Share
1.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:13 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.